Active internal bleeding, history of CVA, within 2 months of intracranial or intraspinal surgery or trauma, intracranial neoplasm, AV malformation or aneurysm, bleeding diathesis, severe uncontrolled hypertension. Since fibrin will be lysed during therapy, careful attention should be given to potential bleeding sites such as sites of catheter insertion and needle puncture sites. Safety and efficacy have not been established in children. Bradycardia, hypotension, cardiogenic shock, arrhythmias, heart failure, cardiac arrest, cardiac tamponade, myocardial rupture recurrent ischemia, reinfarction, mitral regurgitation, pericardial effusion, pericarditis, venous thrombosis and embolism, electromechanical dissociation. Rash, laryngeal edema, anaphylaxis.
Incidence increases with age.
Discontinue therapy immediately as well as any concomitant heparin therapy. Dosage IV Infusion Only AMI, accelerated infusion. 100 mg as a 15-mg IV bolus, followed by 50 mg infused over the next 30 min and then 35 mg infused over the next 60 min. The safety and efficacy of this regimen have only been evaluated using heparin and aspirin concomitantly. AMI, 3-hr infusion.